Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Mirion Technologies, Inc. reports company developments in radiation detection, measurement, analysis and monitoring solutions for nuclear, medical, defense and research markets. Updates commonly cover financial results, orders, guidance, investor presentations and leadership appointments across the Nuclear & Safety and Medical groups.
Mirion's recurring business themes include nuclear power customers, critical radiation safety applications, R&D labs, nuclear facilities and healthcare uses such as Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry and Diagnostic Imaging. News also reflects the completed Paragon Energy Solutions acquisition, which added engineered nuclear-power offerings and is being integrated into the Nuclear & Safety group.
Mirion (NYSE: MIR), a global radiation detection and monitoring solutions provider, announced the completion of the redemption of its outstanding publicly traded warrants. As of May 20, 2024, Mirion redeemed the warrants at $0.10 each. Of the 18,749,779 warrants, 2,131 were exercised for cash, and 18,074,285 were exercised on a cashless basis, resulting in a total of 3,978,418 new common shares issued. The remaining 673,363 unexercised warrants were redeemed for $67,336.30. The public warrants ceased trading on the NYSE before the market opened on May 20, 2024. The private placement warrants remain unaffected and continue to be outstanding. The common shares continue to trade under the symbol 'MIR'. Additional details are available on Mirion’s Investor Relations website.
Mirion (NYSE: MIR) announced that its CEO Thomas Logan and CFO Brian Schopfer will present at Jefferies’ 2024 Global Healthcare Conference in New York, NY. The presentation is scheduled for June 6, 2024, at 4:00 PM ET.
The event will be webcast live and accessible via Mirion's investor relations website, with an archived version available within twelve hours post-event.
Mirion announced its first quarter 2024 financial results, with revenues increasing by 5.8% to $192.6 million and a net loss of $26.5 million. Adjusted EBITDA rose to $39.5 million, and the company reaffirmed its full year guidance, expecting revenue growth of 5% to 7% and adjusted EPS of $0.37-$0.42.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.